Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Solid Tumors

NCT03472352 is registered in ClinicalTrials.gov with Hangzhou Converd Co., Ltd. as lead sponsor.

NCT NCT03472352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03472352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Solid Tumors
Lead sponsor
Hangzhou Converd Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
April 30, 2018
Completion date
April 30, 2019
Enrollment
15 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors